\begin{table*}
\caption{Literuature summary of known DPP4 substrates.}
\label{DPP4-Sub}

\begin{tabular}{|l|l|l|l|c|c|l|c|l|}
    \hline
    \ Categories & Substrates & UniProt ID & N-terminal Seq & Size(aa) \textendash\, Start, End& \textit{In vivo} OR \textit{In vitro} & Biophysiological effects upon cleavage & Half-life (Average) & References \\
    \hline
    \multirow{15}{*}{Immune Response} & CXCL2 & P19875 & AP \textbar\; LATELRCQCL & 73 \textendash\, 35, 107 & \textit{In vitro} & Increased hematopoietic activity & \textendash & \cite{10725737,  Ajami:2008oz} \\
    \hline
    & CXCL6 / GCP-2 & P80162 & GP \textbar\; VSAVLTELR & 75 \textendash\, 38,114 & \textit{In vitro} & Inactivation & \textendash & \cite{Proost:1998kl} \\
    \hline 
    & CXCL9 / MIG & Q07325 & TP \textbar\; VVRKGRCSCI & 103 \textendash\, 23,125 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CXCR3 signaling & 24 mins & \cite{Lambeir:2001ab} \\
    \hline 
    & CXCL10 / IP10 & P02778 & VP \textbar\; LSRTVRCT & 71 \textendash\, 22,94 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CXCR3 signaling & 4 mins & \cite{Lambeir:2001ab, 12173928} \\
    \hline
    & CXCL11 / IP-9 / I-TAC & O14625 & FP \textbar\; MFKRGRCL & 70 \textendash\, 22,94 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CXCR3 signaling & 2 mins & \cite{Proost:1998kl, Lambeir:2001ab, Ludwig:2002aa} \\
    \hline 
    & CXCL12 / SDF1 & P48061 & KP \textbar\; VS \textbar\; LSYRCP & 67(65) \textendash\, 22(24),88 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CXCR4 signaling & \< 1 mins & \cite{Proost:1998kl, Shioda:1998aa, Lambeir:2001ab} \\
    \hline 
    CCL5 / RANTES & P13501 & SP \textbar\; YS \textbar\; SDTTPC & 65(63) \textendash\, 24(26),91  & \textit{In vitro} & Altered receptor specificity; preferentially binds to CCR5 instead of CCR1 & 400 mins & \cite{Oravecz:1997aa, Lambeir:2001ab} \\
    \hline 
    & CCL11 / Eotaxin & P51671 & GP \textbar\; ASVPTTCCF & 72 \textendash\, 24, 97 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CCR3 signaling & 30 mins & \cite{Lambeir:2001ab, Struyf:1999aa, Ajami:2008oz, 18606664} \\
    \hline 
    & CCL22 / MDC & O00626 & GP \textbar\; YGANMEDS & 67 \textendash\, 25,93 & \textit{In vitro} & Inactivation; Reduced chemotactic potential via CCR4 signaling & 1.6 \textbar\; 5.5 mins & \cite{Lambeir:2001ab} \\
    \hline 
    & CCL3L1 / MIP / LD78\beta & P16619 & AP \textbar\; LA \textbar\; ADTPTAC & 68(66) \textendash\, 24(26),93 & \textit{In vitro} & Inactivation; Increased chemotactic potential via CCR1 and CCR5 signaling & 6000 mins & \cite{Proost:1998kl,Lambeir:2001ab} \\
    \hline 
    & MIP1\alpha / LD78\alpha &  P10147 & AD \textbar\; TP \textbar\; TACCFSY & 66(64) \textendash\, 27(29), 92 & \textit{In vitro} & No reported effect & \textendash & \cite{Proost:1998kl) \\
    \hline 
    & Erythropoiethin & P01588 & 
\end{tabular}
\end{table*}